Disclosure of Affiliations, Financial Support, and Mitigating Bias

Speaker Name: Mike Conlon

Affiliations: Please choose the statement that best describes your disclosure: I have no relationships with for-profit or not-for-profit organizations.

Financial Support: Please choose the statement(s) that best describes your disclosure:

This session/program has not received financial or in-kind support.



Comprehensive hospice palliative care delivery and impact on end-of-life care, and family satisfaction with care in Sudbury, Ontario 2012-2015: A propensity score matched retrospective observational study using administrative data

MIKE CONLON EPIDEMIOLOGIST, HSNRI SITE DIRECTOR, ICES NORTH



Health Sciences North Research Institute

Institut de recherches d'Horizon Santé-Nord



Northern Ontario School of Medicine École de médecine du Nord de l'Ontario $\dot{P} \cdot \nabla \Omega$ $\dot{A}^{2} \cup \dot{Z} \dot{D}$ $L^{mp} \dot{P} \cdot \Delta \Delta^{2} \dot{D} \cdot \dot{\Delta}^{2}$



Laurentian University Université Laurentienne

Institute for Clinical Evaluative Sciences

Mission, Vision & Values

ICES is a not-for-profit research institute encompassing a community of research, data and clinical experts, and a secure and accessible array of Ontario's health-related data.

ICES MISSION

Our mission is research excellence resulting in trusted evidence that makes policy better, health care stronger and people healthier.

ICES VISION

Our vision is to be a world-leading research institute where data and discovery improve health and health care.

ICES VALUES

- Excellence demonstrated by the quality, innovation and rigour of our work
- Integrity expressed through independence, transparency and impartiality
- Relevance by providing high-value, timely results that are responsive to health priorities
- Collaboration through effective partnerships, accessible data and a spirit of openness
- Respect exemplified by responsible stewardship, inclusiveness and appreciation of each other





WHAT'S NEW AT ICES



News Releases | 11/2/2017

International research collaboration publishes guidelines in The Lancet on the use of Indigenous health data

An international team of researchers led by ICES have published governance guidelines in The Lancet for the use of Indigenous health data.



Types of ICES data

ICES holds several kinds of data in the following categories:

1. HEALTH SERVICES ADMINISTRATIVE DATA

- Physician billings
- Prescription drug claims for those 65 and older
- Inpatient hospital discharges
- Emergency and ambulatory care visits
- Home care and rehabilitation claims
- Long-term care visits
- 2. PEOPLE AND GEOGRAPHY
- Population estimates
- Canada census profiles
- Death records
- All Ontarians eligible for health care benefits

Limitations:

- 1) Not designed with research in mind but routinely collected information
- 2) Limited clinical information, no test results, proxy measures often used
- 3) Data lag
- 4) Data somewhat remuneration dependent

3. SPECIAL COLLECTIONS

- Registries (cancer, stroke, cardiac care)
- First Nations and Métis
- Developmental disabilities
- Federal Immigration Information

4. DERIVED CONDITIONS

- Diabetes
- Hypertension
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Acute myocardial infarction
- Congestive heart failure
- Inflammatory bowel disease

5. SURVEY DATA

Health Surveys

6. CLINICAL DATA

- Patient information collected with consent in primary clinical studies
- Supplementary clinical data from individual hospitals and other institutions.

7. CHART ABSTRACTION DATA

Information on processes and quality of care collected directly from patients' charts



ICES CORE Data Repository: Coded and Linkable





Comprehensive hospice palliative care delivery and impact on end-of-life care, and family satisfaction with care in Sudbury, Ontario 2012-2015: A propensity score matched retrospective observational study using administrative data

Mike Conlon, Epidemiology HSNRI, Site Director ICES North Joseph Caswell, Epidemiology HSNRI, Local Lead Analyst ICES North Andrew Knight, Palliative Symptom Management Clinic Barbara Ballantyne, Palliative Symptom Management Clinic Stacey Santi, Epidemiology HSNRI Peggy Meigs, Epidemiology HSNRI Craig Earle, Canadian Partnership Against Cancer Mark Hartman, HSN/HSNRI

Introduction

For cancer patients facing a terminal illness, a hospice palliative care (HPC) approach is an important component of quality care and can offer many benefits to patients and their families

- Pain and symptom management
- Coordination of care
- Improved quality of life and family caregiver satisfaction

There may also be substantial benefits to the health system that may include decreased use of potentially aggressive end-of-life care, that is often not the wish of patients, and is costly to the health system

The Symptom Management Program (SMP) at the Northeast Cancer Centre of Health Sciences North is an ambulatory program that uses a HPC approach for cancer patients with terminal disease.



Purpose

- Determine the associations between delivery of comprehensive HPC and the use of potentially aggressive end-of-life care in the last month of life, and place of death, when compared to a matched cohort of palliative patients who reside within the Greater Sudbury and District;
- Assess family caregiver satisfaction with advancer cancer care delivered through the SMP

Methods

Design and Setting

Retrospective study of palliative care decedents enrolled in the Symptom Management Program (SMP)

The SMP

- Ambulatory program that uses an HPC approach for cancer patients with terminal disease100-120 active patients per year
- Receives about 350 referrals per year
- Majority of people who attend reside in Greater Sudbury or District
- Began operation in 2011

Data Sources

- SMP cohort defined from medical records at the North East Regional Cancer Program of HSN (2012-2015)
- Data sharing agreement allowed us to share the roster with ICES
- Data linkages with administrative data allowed us to define a number of study outcomes, and as the source for a matched control series
- RPDB, OCR, OHIP, CIHI NACRS, DAD
- Potential controls were defined from group of decedent residents of same area, diagnosed with cancer, deceased, had lived 30 days from diagnoses to death, who died within 2012-2015, were not identified as SMP



ICES CORE Data Repository: Coded and Linkable



ICES North

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT



From the Ontario Institute for Cancer Research; Odette Cancer Centre; Institute for Clinical Evaluative Sciences, Toronto, Ontario; and Dana-Farber Cancer Institute, Boston, MA.

Submitted August 2, 2010; accepted January 11, 2011; published online ahead of print at www.jco.org on March 14, 2011.

Supported by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario and by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care; and by Grant No. CA 91753-02 from the National Cancer Institute.

The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by Ontario Institute for Cancer Research, Institute for Clinical Evaluative Sciences, the Government of Ontario, or Ontario Ministry of Health and Long-Term Care is intended or should be informed.

Presented at the institute on innovations in Pallative Care in Toronto, Ontario, in May 2009.

Trends in the Aggressiveness of End-of-Life Cancer Care in the Universal Health Care System of Ontario, Canada

Thi H. Ho, Lisa Barbera, Refik Saskin, Hong Lu, Bridget A. Neville, and Craig C. Earle

A B S T R A C T

Purpose



To describe trends in the aggressiveness of end-of-life (EOL) cancer care in a universal health care system in Ontario, Canada, between 1993 and 2004, and to compare with findings reported in the United States.

Methods

A population-based, retrospective, cohort study that used administrative data linked to registry data. Aggressiveness of EOL care was defined as the occurrence of at least one of the following indicators: last dose of chemotherapy received within 14 days of death; more than one emergency department (ED) visit within 30 days of death; more than one hospitalization within 30 days of death; or at least one intensive care unit (ICU) admission within 30 days of death.

Results

Among 227,161 patients, 22.4% experienced at least one incident of potentially aggressive EOL cancer care. Multivariable analyses showed that with each successive year, patients were significantly more likely to encounter some aggressive intervention (odds ratio, 1.01; 95% CI, 1.01 to 1.02). Multiple emergency department (ED) visits, ICU admissions, and chemotherapy use increased significantly over time, whereas multiple hospital admissions declined (P < .05). Patients were more likely to receive aggressive EOL care if they were men, were younger, lived in rural regions, had a higher level of comorbidity, or had breast, lung, or hematologic malignancies. Chemotherapy and ICU utilization were lower in Ontario than in the United States.

Conclusion

Aggressiveness of cancer care near the EOL is increasing over time in Ontario, Canada, although overall rates were lower than in the United States. Health system characteristics and patient or physician cultural factors may play a role in the observed differences.

J Clin Oncol 29:1587-1591. @ 2011 by American Society of Clinical Oncology







FAMCARE Scale-Measuring Satisfaction with Care

- The FAMCARE Scale is a tool used to measure family satisfaction with advanced cancer care. It measures different areas of care such as availability of care, physical patient care, psychosocial care, and information giving. The original scale is a "20-item Likert-type scale measuring the degree to which family members are content with the health care provider behaviours directed toward to patient and themselves" (Kristjanson, 1993, p. 696).
- The FAMCARE Scale can be given to family members while a patient is receiving palliative care or at some point after a patient's death.
- The FAMCARE Scale is a validated instrument and it is used in such places as North America, Australia, Europe, and Canada.



Statistical Analyses

Patient characteristics between treatment group (SMP) and control group (Non-SMP) were assessed using standardized differences

- Unadjusted and propensity score-matched analyses defined proportions, used to calculate absolute risk reduction (ARR), number needed to treat (NNT) and relative risk (RR)
 - Logistic regression used to define propensity scores with treatment as outcome and all covariates as independent measures; treatment group was matched to controls (greedy matching) using a caliper width (0.05) times the standard deviation of the logit propensity scores
 - Standardized differences were calculated before and after matching
 - Paired analyses to assess
- For FAMCARE questionnaire, scored following recommendations of the author





Fig. 1. Flow chart outlining data build including linkages

Table 1. Frequencies, descriptive statistics, and standardized differences (d) of each covariate before and after propensity score matching in palliative patients who received hospice palliative care from the SMP and those who did not.

	E	Before Matching		After Matching			
Covariate	Non-SMP	SMP	d	Non-SMP	SMP	d	
	n = 1,613	n = 914		n = 754	n = 754		
Age Group – n (%)			0.58			0.08	
< 55	68 (4.22)	101 (11.05)		58 (7.69)	69 (9.15)		
55-64	180 (11.16)	204 (22.32)		131 (17.37)	145 (19.23)		
65-74	356 (22.07)	283 (30.96)		234 (31.03)	234 (31.03)		
75+	1,009 (62.55)	326 (35.67)		331 (43.90)	306 (40.58)		
Sex – n (%)			0.05			0.00	
Male	926 (57.41)	504 (55.14)		431 (57.16)	431 (57.16)		
Female	687 (42.59)	410 (44.86)		323 (42.84)	323 (42.84)		
Charlson Index –	3.81 ±2.88	5.23 ±2.82	0.51	4.92 ±2.90	4.91 ±2.83	0.01	
mean ±SD							
Duration of Disease – mean ±SD	6.79 ±6.35	3.45 ±4.39	0.55	3.48 ±4.23	3.79 ±4.64	0.07	

Table 1 (con't). Frequencies, descriptive statistics, and standardized differences (d) of each covariate before and after propensity score matching in palliative patients who received hospice palliative care from the SMP and those who did not.

ICES North

	Before Matching			After Matching			
Covariate	Non-SMP	SMP	d	Non-SMP	SMP	d	
	n = 1,613	n = 914		n = 754	n = 754		
Cancer Type – n (%)			0.44			0.07	
Breast	142 (8.80)	59 (6.46)		49 (6.50)	48 (6.37)		
Lung	225 (13.95)	264 (28.88)		170 (22.55)	190 (25.20)		
Colorectal	232 (14.38)	96 (10.50)		87 (11.54)	88 (11.67)		
Prostate	253 (15.69)	67 (7.33)		64 (8.49)	65 (8.62)		
Other	761 (47.18)	428 (46.83)		384 (50.93)	363 (48.14)		
Rural – n (%)			0.18			0.01	
No	1,397 (86.61)	842 (92.12)		687 (91.11)	688 (91.25)		
Yes	216 (13.39)	72 (7.88)		67 (8.89)	66 (8.75)		
Income Quintile – n (%)			0.14			0.06	
1 (lowest)	443 (27.46)	208 (22.76)		165 (21.88)	185 (24.54)		
2	324 (20.09)	188 (20.57)		163 (21.62)	159 (21.09)		
3	269 (16.68)	185 (20.24)		149 (19.76)	143 (18.97)		
4	327 (20.27)	175 (19.15)		147 (19.50)	140 (18.57)		
5	250 (15.50)	158 (17.29)		130 (17.24)	127 (16.84)		
Index Year – n (%)			0.15			0.02	
2012	407 (25.23)	190 (20.79)		166 (22.02)	165 (21.88)		
2013	436 (27.03)	232 (25.38)		210 (27.85)	203 (26.92)		
2014	397 (24.61)	228 (24.95)		183 (24.27)	188 (24.93)		
2015	373 (23.12)	264 (28.88)		195 (25.86)	198 (26.26)		

Table 2. Study outcomes of the use of aggressive end-of-life care in patients who participated in SMP and those with a palliative designation but did not receive HPC.

Outcome	p*	SMP %	Non-SMP %	ARR % (95% CI)	NNT (95% CI)	RR (95% CI)
Hospitalization	0.04	4.77	7.56	2.79 (2.76-2.82)	35.84 (35.45-36.25)	0.63 (0.42-0.95)
Emergency Department	0.03	9.42	13.13	3.71 (3.66-3.76)	26.95 (26.57-27.35)	0.72 (0.53-0.97)
Chemotherapy	0.20	1.46	2.52	-	-	-
Intensive Care Unit	<0.001	1.06	12.20	11.14 (11.11-11.17)	8.98 (8.95-9.00)	0.09 (0.04-0.18)
Any AEoLC	<0.001	12.47	25.20	12.73 (12.65-12.81)	7.86 (7.81-7.91)	0.50 (0.39-0.62)
Death in Acute Care	<0.001	24.14	44.03	19.89 (19.78-20.00)	5.03 (5.00-5.06)	0.55 (0.47-0.64)

Table 3. Descriptive statistics and results for FAMCARE scales completed by family members of patients who received hospice palliative care treatment from SMP (n=96).

Aggressive End-of-Life Care (Any) mean ±SD			Death in Acute Care mean ±SD		·
No (n = 86)	Yes (n = 10)		No (n = 68)	Yes (n = 28)	
86.50 ±10.93	79.00 ±10.94	0.03	85.22 ±12.09	86.93 ±8.32	0.80
21.26 ±3.41	19.10 ±2.60	0.02	20.88 ±3.70	21.39 ±2.50	0.95
30.17 ±3.84	28.30 ±3.97	0.11	29.75 ±4.18	30.54 ±3.01	0.60
17.41 ±2.41	15.80 ±2.15	0.04	17.25 ±2.59	17.21 ±2.03	0.69
17.66 ±2.40	15.80 ±3.12	0.02	17.34 ±2.80	17.79 ±1.75	0.80
	No Immetal No (n = 86) 86.50 ±10.93 21.26 ±3.41 30.17 ±3.84 17.41 ±2.41 17.66 ±2.40 17.66 ±2.40	mean ±SDNoYes(n = 86)(n = 10) 86.50 ± 10.93 79.00 ± 10.94 21.26 ± 3.41 19.10 ± 2.60 30.17 ± 3.84 28.30 ± 3.97 17.41 ± 2.41 15.80 ± 2.15 17.66 ± 2.40 15.80 ± 3.12	NoYes(n = 86)(n = 10) 86.50 ± 10.93 79.00 ± 10.94 0.03 21.26 ± 3.41 19.10 ± 2.60 0.02 30.17 ± 3.84 28.30 ± 3.97 0.11 17.41 ± 2.41 15.80 ± 2.15 0.04 17.66 ± 2.40 15.80 ± 3.12 0.02	No (n = 86)Yes (n = 10)No (n = 68) 86.50 ± 10.93 79.00 ± 10.94 0.03 85.22 ± 12.09 21.26 ± 3.41 19.10 ± 2.60 0.02 20.88 ± 3.70 30.17 ± 3.84 28.30 ± 3.97 0.11 29.75 ± 4.18 17.41 ± 2.41 15.80 ± 2.15 0.04 17.25 ± 2.59 17.66 ± 2.40 15.80 ± 3.12 0.02 17.34 ± 2.80	Mean \pm SDNoYes (n = 86)No (n = 10)Yes (n = 28)86.50 \pm 10.9379.00 \pm 10.940.0385.22 \pm 12.0986.93 \pm 8.3221.26 \pm 3.4119.10 \pm 2.600.0220.88 \pm 3.7021.39 \pm 2.5030.17 \pm 3.8428.30 \pm 3.970.1129.75 \pm 4.1830.54 \pm 3.0117.41 \pm 2.4115.80 \pm 2.150.0417.25 \pm 2.5917.21 \pm 2.0317.66 \pm 2.4015.80 \pm 3.120.0217.34 \pm 2.8017.79 \pm 1.75

Interpretation

<u>3 Key Findings:</u>

1. Enrolment in the SMP was protective for most measures of potentially aggressive end-of-life care for residents in Greater Sudbury and District

- Risk reductions in ICU admissions
- PC most common reasons for hospital admissions
- 43% higher costs for those managed aggressively
- 2. Provision of HPC was protective for death in the acute care setting
 - While admission to acute care hospital could be appropriate because of disease progression, optimal treatment, or caregiver respite, overuse may signal potential gap in palliative services
- 3. Family caregiver assessed satisfaction with care appeared high
 - Difference in assessed satisfaction with aggressive EOL, not with place of death

Limitations of the study:

- 1. Some variables were not available for analysis
- 2. System level measures—appropriateness or quality
- 3. HPC in controls
- 4. FAMCARE generalizability

Funding Statement/ICES Disclaimer

The research for this study was funded by a Principal Investigator Grant to M. Conlon from the Northern Cancer Foundation (NCF).

This study was also supported through provision of data by the Institute for Clinical Evaluative Sciences (ICES) and Cancer Care Ontario (CCO) and through funding support to ICES from an annual grant by the Ministry of Health and Long-Term Care (MOHLTC) and the Ontario Institute for Cancer Research (OICR). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES, CCO, OICR or the Government of Ontario is intended or should be inferred. Parts of this material are based on data and/or information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed in the material are those of the author(s), and not necessarily those of CIHI. Parts of this material are also based on data and information provided by Cancer Care Ontario (CCO). The opinions, results, view, and conclusions reported in this paper are those of the author(s) and do not necessarily reflect those of CCO. No endorsement by CCO is intended or should be inferred.

Thank You



For more information on ICES North contact: icesnorthadmin@ices.on.ca mconlon@ices.on.ca mconlon@hsnri.ca